Adenosine analogues as inhibitors of P2Y12 receptor mediated platelet aggregation.
Modified adenosine derivatives may lead to the development of P2Y(12) antagonists that are potent, selective, and bind reversibly to the receptor. Analogues of 2',3'-trans-styryl acetal-N6-ureido-adenosine monophosphate were prepared by modification of the 5'-position. The resulting analogues were tested for P2Y(12) antagonism in a platelet aggregation assay.
Douglass
James G
JG
Inspire Pharmaceuticals, Inc., Department of Medicinal Chemistry, 4222 Emperor Boulevard, Suite 200, Durham, NC 27703, USA.
deCamp
J Bryan
JB
Fulcher
Emilee H
EH
Jones
William
W
Mahanty
Sanjoy
S
Morgan
Anna
A
Smirnov
Dima
D
Boyer
José L
JL
Watson
Paul S
PS
D000244:Adenosine Diphosphate / Q000378:metabolism; D000249:Adenosine Monophosphate / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology*; D000255:Adenosine Triphosphate / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008565:Membrane Proteins / Q000037:antagonists & inhibitors*; D015394:Molecular Structure; D010974:Platelet Aggregation / Q000187:drug effects*; D058919:Purinergic P2 Receptor Antagonists; D058925:Receptors, Purinergic P2Y12
D008565:Membrane Proteins; C548576:P2RY12 protein, human; D058919:Purinergic P2 Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D000249:Adenosine Monophosphate; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate